Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1993 Sep 11;307(6905):663–666. doi: 10.1136/bmj.307.6905.663

Diagnosis and treatment of systemic lupus erythematosus.

P J Venables 1
PMCID: PMC1678962  PMID: 8401055

Full text

PDF
663

Images in this article

663FIG 1
on p.663
663FIG 2
on p.663
664FIG 3
on p.664
664FIG 4
on p.664

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barron K. S., Person D. A., Brewer E. J., Jr, Beale M. G., Robson A. M. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr. 1982 Jul;101(1):137–141. doi: 10.1016/s0022-3476(82)80203-5. [DOI] [PubMed] [Google Scholar]
  2. Edwards J. C., Snaith M. L., Isenberg D. A. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment. Ann Rheum Dis. 1987 Oct;46(10):773–776. doi: 10.1136/ard.46.10.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ginzler E. M., Antoniadis I. Clinical manifestations of systemic lupus erythematosus, measures of disease activity, and long-term complications. Curr Opin Rheumatol. 1992 Oct;4(5):672–680. [PubMed] [Google Scholar]
  4. Gladman D. D. Prognosis of systemic lupus erythematosus and factors that affect it. Curr Opin Rheumatol. 1992 Oct;4(5):681–687. [PubMed] [Google Scholar]
  5. Kimberly R. P. Treatment. Corticosteroids and anti-inflammatory drugs. Rheum Dis Clin North Am. 1988 Apr;14(1):203–221. [PubMed] [Google Scholar]
  6. Levey A. S., Lan S. P., Corwin H. L., Kasinath B. S., Lachin J., Neilson E. G., Hunsicker L. G., Lewis E. J. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med. 1992 Jan 15;116(2):114–123. doi: 10.7326/0003-4819-116-2-114. [DOI] [PubMed] [Google Scholar]
  7. Lieberman J. D., Schatten S. Treatment. Disease-modifying therapies. Rheum Dis Clin North Am. 1988 Apr;14(1):223–243. [PubMed] [Google Scholar]
  8. Lubbe W. F., Butler W. S., Palmer S. J., Liggins G. C. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet. 1983 Jun 18;1(8338):1361–1363. doi: 10.1016/s0140-6736(83)92141-4. [DOI] [PubMed] [Google Scholar]
  9. Marguerie C., Bunn C. C., Beynon H. L., Bernstein R. M., Hughes J. M., So A. K., Walport M. J. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990 Oct;77(282):1019–1038. doi: 10.1093/qjmed/77.1.1019. [DOI] [PubMed] [Google Scholar]
  10. Miller M. L. Treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 1992 Oct;4(5):693–699. [PubMed] [Google Scholar]
  11. Silman A. J., Petrie J., Hazleman B., Evans S. J. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis. 1988 Dec;47(12):988–992. doi: 10.1136/ard.47.12.988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  13. Vyse T. J., Walport M. J. Connective tissue diseases: advances in diagnosis and management. 1993 Jul 14-Aug 17Br J Hosp Med. 50(2-3):121–132. [PubMed] [Google Scholar]
  14. Wilke W. S., Krall P. L., Scheetz R. J., Babiak T., Danao T., Mazanec D. J., Segal A. M., Clough J. D. Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin Exp Rheumatol. 1991 Nov-Dec;9(6):581–587. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES